130605-98-0

Basic information

• Product Name: PIPERIDIN-2-YL-PYRROLIDIN-1-YL-METHANONE
• Synonyms: ART-CHEM-BB B025047;AKOS B025047;PIPERIDIN-2-YL-PYRROLIDIN-1-YL-METHANONE;1-(2-Piperidinylcarbonyl)-pyrrolidine HCl;2-piperidinyl-1-pyrrolidinylmethanone;2-piperidyl-pyrrolidin-1-yl-methanone
• CAS NO: 130605-98-0
• Molecular Formula: C₁₀H₁₈N₂O
• Molecular Weight: 182.26
• Mol File: 130605-98-0.mol

Chemical Properties

• Boiling Point: 335.3°C at 760 mmHg
• Flash Point: 156.6°C
• Appearance: /
• Density: 1.074g/cm³
• Vapor Pressure: 0.000121mmHg at 25°C
• Refractive Index: 1.513
• CAS DataBase Reference: PIPERIDIN-2-YL-PYRROLIDIN-1-YL-METHANONE(CAS DataBase Reference)
• NIST Chemistry Reference: PIPERIDIN-2-YL-PYRROLIDIN-1-YL-METHANONE(130605-98-0)
• EPA Substance Registry System: PIPERIDIN-2-YL-PYRROLIDIN-1-YL-METHANONE(130605-98-0)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 130605-98-0(Hazardous Substances Data)

Usage

Uses

Used in Recreational Drug Scene:
PIPERIDIN-2-YL-PYRROLIDIN-1-YL-METHANONE is used as a psychoactive substance for its stimulant and entactogenic effects, similar to those of MDMA. It is favored for its ability to influence the release and reuptake of neurotransmitters in the brain, leading to altered states of consciousness and mood enhancement.
Used in Research and Development:
In the scientific community, PIPERIDIN-2-YL-PYRROLIDIN-1-YL-METHANONE may be utilized as a research chemical to study the effects of psychoactive substances on neurotransmitter systems. This can contribute to a better understanding of the mechanisms of action of MDMA and related compounds, potentially leading to advancements in the development of therapeutic agents for various neurological and psychiatric conditions.

InChI:InChI=1/C10H18N2O/c13-10(12-7-3-4-8-12)9-5-1-2-6-11-9/h9,11H,1-8H2

Upstream product

• 4043-87-2 pipecolic Acid 
• 130497-14-2 (+/-)-[(N-ethoxycarbonyl)piperidine]-2-carboxylic acid 
• 123-75-1 pyrrolidine 
• 130606-00-7 piperidine-2-carbonyl chloride 

Downstream Products

• 130497-48-2 2-(4-Cyclohexyl-phenyl)-1-(2-pyrrolidin-1-ylmethyl-piperidin-1-yl)-ethanone 
• 130497-39-1 ZT 52656A 
• 130497-44-8 1-(2-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-2-(2-trifluoromethyl-phenyl)-ethanone 
• 128103-41-3 [3H]-BRL 52537 
• 130497-46-0 2-(3,4-Dimethyl-phenyl)-1-(2-pyrrolidin-1-ylmethyl-piperidin-1-yl)-ethanone 
• 115642-93-8 1-(4-Bromophenylacetyl)-2-(1-pyrrolidinylmethyl)piperidine 
• 130497-41-5 2-(4-Chloro-phenyl)-1-(2-pyrrolidin-1-ylmethyl-piperidin-1-yl)-ethanone 
• 130497-42-6 2-(4-Fluoro-phenyl)-1-(2-pyrrolidin-1-ylmethyl-piperidin-1-yl)-ethanone 
• 130497-49-3 2-(4-Hydroxy-phenyl)-1-(2-pyrrolidin-1-ylmethyl-piperidin-1-yl)-ethanone 
• 130497-45-9 1-(2-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-2-p-tolyl-ethanone 
• 138154-84-4 1-<(3,4-dichlorophenyl)acetyl>-2-methyl-2-(1-pyrrolidinylmethyl)piperidine 
• 138155-36-9 phenylmethyl 2-(2-propenyl)-2-(1-pyrrolidinylcarbonyl)-1-piperidinecarboxylate 
• 138154-85-5 1-<(3,4-dichlorophenyl)acetyl>-2-(2-propenyl)-2-(1-pyrrolidinylmethyl)piperidine 
• 138154-81-1 phenylmethyl 2-methyl-2-(1-pyrrolidinylcarbonyl)-1-piperidinecarboxylate 

Relevant articles and documents

2-Aminomethyl piperidines as novel urotensin-II receptor antagonists

A series of 2-aminomethyl piperidines has been discovered as novel urotensin-II receptor antagonists. The synthesis, initial structure-activity relationships, and optimization of the initial hit that resulted in the identification of potent, cross-species active, and functional urotensin-II receptor antagonists such as 1a and 11a are described.

(2S)-1-(arylacetyl)-2-(aminomethyl)piperidine derivatives: Novel, highly selective κ opioid analgesics

This paper describes the synthesis and structure-activity relationships as κ opioid analgesics of a novel class of 1-(arylacetyl)-2-(aminomethyl)piperidine derivatives (8). The active conformation of the pharmacophore, with a torsional angle (N1C2C7N8) of 60°, was defined with computational studies and 1H NMR. A quantitative structure-activity relationship study of the arylacetic moiety substitution indicated that the presence of an electron-withdrawing and lipophilic substituent in para and/or meta positions is required for good analgesic activity and κ affinity. The lead compounds (2S)-1-[(3,4-dichlorophenyl)acetyl]-2-(pyrrolidin-1-ylmethyl) piperidine hydrochloride (14) and (2S)-1-[[4-(trifluoromethyl)phenyl]acetyl]-2-(pyrrolidin-1- ylmethyl)piperidine hydrochloride (21) are the most κ/μ selective (respectively 6500:1 and 4100:1) and among the most potent (K(i) κ 0.24 and 0.57 nM, respectively) κ ligands identified so far. In the mouse tail flick model of antinociception, compound 14 (ED50 = 0.05 mg/kg sc) was 25 times more potent than morphine and 16 times more potent than the standard κ ligand U-50488.